HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor via intranasal administration

• Үндсэн зохиолчид: Ying Lu (Зохиогч), Fan Shen (Зохиогч), Wen-Qiang He (Зохиогч), An-Qi Li (Зохиогч), Ming-Hua Li (Зохиогч), Xiao-Li Feng (Зохиогч), Yong-Tang Zheng (Зохиогч), Wei Pang (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2023-08-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

The continuously emerging SARS-CoV-2 variants pose a great challenge to the efficacy of current drugs, this necessitates the development of broad-spectrum antiviral drugs. In the previous study, we designed a recombinant protein, heptad repeat (HR) 121, as a variant-proof vaccine. Here, we found it...